scPharmaceuticals (SCPH) Provides Business Update on FUROSCIX

Go back to scPharmaceuticals (SCPH) Provides Business Update on FUROSCIX

scPharmaceuticals Provides Business Update

October 8, 2020 8:00 AM EDT

BURLINGTON, Mass.--(BUSINESS WIRE)-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today provided a business update on FUROSCIX®, its investigational proprietary formulation of furosemide for subcutaneous administration.

As we look forward to our upcoming December 30, 2020 PDUFA date for FUROSCIX, we are building out what we believe is a world-class commercial team capable of executing a successful product launch, if approved, stated John Tucker, president and chief executive officer of scPharmaceuticals. In... More